NitroMed, Inc. Announces Sale Of Common Stock

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 25, 2006--NitroMed, Inc. (NASDAQ:NTMD) announced today that it has entered into agreements to sell approximately 6.1 million shares of its common stock to selected institutional investors at a price of $10.25 per share. The shares are being offered under NitroMed’s effective shelf registration statement previously filed with the Securities and Exchange Commission. Proceeds to NitroMed from this registered direct offering, net of offering expenses and placement agency fees, total approximately $58.6 million. The net proceeds of the financing will be used for general corporate purposes, including the continued commercial launch of NitroMed’s first marketed product, BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride).

MORE ON THIS TOPIC